Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Retained Earnings (2016 - 2025)

AC Immune has reported Retained Earnings over the past 11 years, most recently at -$549.3 million for Q4 2025.

  • Quarterly Retained Earnings fell 30.67% to -$549.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$549.3 million through Dec 2025, down 30.67% year-over-year, with the annual reading at -$549.3 million for FY2025, 30.67% down from the prior year.
  • Retained Earnings was -$549.3 million for Q4 2025 at AC Immune, down from -$524.7 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$236.9 million in Q1 2022 and troughed at -$356.5 billion in Q4 2023.
  • The 5-year median for Retained Earnings is -$411.5 million (2024), against an average of -$56.3 billion.
  • Year-over-year, Retained Earnings tumbled 193052.78% in 2021 and then soared 99.88% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$217.9 billion in 2021, then skyrocketed by 99.87% to -$274.1 million in 2022, then tumbled by 129971.79% to -$356.5 billion in 2023, then soared by 99.88% to -$420.4 million in 2024, then tumbled by 30.67% to -$549.3 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Retained Earnings are -$549.3 million (Q4 2025), -$524.7 million (Q3 2025), and -$491.6 million (Q2 2025).